[COO] Cooper Companies Thesis 2026: Myopia Management Drives Contact Lens Premium Growth
Key Takeaways
- Myopia Management Acceleration: Selected ~$200M+ FY2025 myopia management revenue (selected MiSight 1 day daily disposable contact lens for myopia control + Brilliant Futures clinical management program); selected post-2024 ~30-50% YoY growth; selected ~30M+ pediatric myopia population in US/Europe/Asia targeted; FY2026 expected myopia management toward $300-400M (+50%+ growth) on continued pediatric adoption + selected international expansion.
- CooperVision Contact Lens Leadership: CooperVision revenue ~$2.9B FY2025 (~70% of total; +6-9% YoY); selected #2 global soft contact lens supplier (vs Johnson & Johnson Acuvue #1; selected ~25% global share); selected MyDay + Biofinity + clariti + selected daily disposable + monthly portfolio; FY2026 expected CooperVision toward $3.1-3.2B (+6-10%) on selected daily disposable conversion + myopia management acceleration.
- CooperSurgical Fertility/Women's Health: CooperSurgical revenue ~$1.2B FY2025 (~30% of total; +0-5% YoY); selected fertility IVF (selected ~$500M+ revenue including IUI + IVF supplies + cryopreservation post-2021 Generate Life Sciences $1.6B acquisition) + PARAGARD copper IUD ($150M+ revenue) + selected; FY2026 expected stable +3-7%.
- No Dividend + Buyback Discipline: $0/share dividend FY2025 (no dividend; selected unique among medical device peers; selected continued capital efficiency over income preference); modest ~$200-400M buybacks; investment-grade Baa2/BBB credit ratings; FCF $400-600M; selected continued M&A optionality (selected fertility + selected myopia adjacencies).
Company Background
The Cooper Companies, Inc. (NYSE: COO; commonly Cooper) is the leading global medical device firm focused on contact lenses + women's health/fertility solutions. Founded 1958 (selected ~67-year heritage; selected initial focus on selected medical devices expanding through ~67-year history into selected contact lens + selected fertility specialties); IPO 1983 NYSE; selected major transformative acquisitions including selected 2005 Ocular Sciences $1.2B (contact lenses) + 2014 Sauflon Pharmaceuticals $1.2B (selected silicone hydrogel) + 2015 PARAGARD $1.1B (copper IUD) + 2021 Generate Life Sciences $1.6B (fertility expansion) + selected various smaller fertility tuck-ins.
Headquartered in San Ramon California; ~16,000+ employees globally with FY2025 (fiscal year ending October 2026) revenue ~$4.1-4.3B (+5-8% YoY) generating ~$700-850M net income (~16-19% net margin) and ~$3.30-3.80 EPS on ~200M diluted shares.
The company operates two reporting segments: CooperVision ~70% of revenue ($2.9B — selected leading global soft contact lens manufacturer focused on daily disposable + monthly portfolio; selected MyDay + Biofinity + clariti + selected; selected ~25% global market share; selected #2 globally vs Johnson & Johnson Acuvue ~30% share; selected post-2024 myopia management acceleration via MiSight 1 day) and CooperSurgical ~30% ($1.2B — selected women's health + fertility solutions including selected fertility IVF supplies + IUI + cryopreservation + PARAGARD copper IUD + selected gynecologic surgical + selected obstetric).
CEO Al White since May 2018 (~7-year tenure; succeeded Robert Weiss CEO 2007-May 2018 retired who led 2007-2018 strategic transformation including selected 2014 Sauflon Pharmaceuticals + 2015 PARAGARD acquisitions; White ex-CooperVision EVP 2014-2018 + ex-various Cooper roles 2007-2014 + ex-Bausch & Lomb + ex-various medical device ~30-year career). Selected internal succession reflected board's preference for operational continuity through selected myopia management strategic acceleration.
Myopia Management Acceleration: ~$200M+ to ~$300-400M Trajectory
Cooper's myopia management strategic catalyst represents selected most differentiated growth driver vs traditional contact lens cycle. Selected MiSight 1 day daily disposable contact lens for myopia control (~$200M+ FY2025 revenue; selected ~50% global myopia management contact lens market share; selected only FDA-approved daily disposable for myopia control in children ages 8-12). Selected Brilliant Futures clinical management program providing eye-care professionals with selected myopia management protocols + selected ongoing patient support.
Selected pediatric myopia epidemic: ~30M+ children in US/Europe/Asia with myopia (selected ~5x prevalence increase since 1980s); selected projected ~50% global pediatric myopia prevalence by 2030 (selected ~$5-10B+ global myopia management TAM by 2030); selected post-2024 ~30-50% YoY growth in MiSight adoption.
FY2026 expected myopia management toward $300-400M (+50%+ growth) reflecting: (i) continued pediatric adoption acceleration; (ii) selected international expansion (selected EMEA + APAC); (iii) selected new product launches (selected MiSight refinements + selected adjacent products); (iv) selected eye-care professional Brilliant Futures program adoption.
Material change rule: myopia management growth decelerates below 25% YoY (would signal severe pediatric adoption deceleration; ~$50-100M annual revenue at-risk per 10pp myopia growth deceleration) OR major MiSight competitive substitution (selected Johnson & Johnson + Bausch & Lomb potential entrants).
CooperVision Contact Lens Leadership: $2.9B Trajectory
CooperVision revenue ~$2.9B FY2025 (~70% of total; +6-9% YoY) reflects: (i) selected MyDay daily disposable (selected $500M+ revenue; selected silicone hydrogel premium daily); (ii) selected Biofinity monthly silicone hydrogel (selected $200M+); (vi) selected international markets ~50%+ revenue.$700M+ revenue; selected dominant monthly portfolio); (iii) selected clariti daily disposable ($400-500M revenue; selected mid-tier daily); (iv) selected toric (astigmatism correction) + multifocal + selected specialty contact lenses; (v) selected MiSight myopia management (
FY2026 expected CooperVision toward $3.1-3.2B (+6-10%) reflecting: (i) selected daily disposable conversion (selected ~30-40% global daily disposable penetration vs ~70%+ in selected developed markets); (ii) myopia management acceleration; (iii) selected silicone hydrogel premium conversion; (iv) selected price/mix improvement.
CooperSurgical Fertility + Women's Health
CooperSurgical revenue $1.2B FY2025 ($150M+ revenue; selected post-2015 acquisition); (iii) selected gynecologic surgical + selected obstetric. FY2026 expected stable +3-7%.30% of total; +0-5% YoY) reflects: (i) selected fertility solutions ($500M+; selected IVF supplies + IUI + cryopreservation post-2021 Generate Life Sciences $1.6B integration); (ii) PARAGARD copper IUD (
Key Core Metrics
| Metric | FY2022 | FY2023 | FY2024 | FY2025E | FY2026E |
|---|---|---|---|---|---|
| Total Revenue | $3.31B | $3.59B | $3.90B | $4.1-4.3B | $4.4-4.6B |
| CooperVision | $2.27B | $2.45B | $2.65B | $2.9B | $3.1-3.2B |
| CooperSurgical | $1.04B | $1.14B | $1.25B | $1.2B | $1.25-1.35B |
| Myopia Management | $80M | $130M | $180M | $200M+ | $300-400M |
| Adj. Operating Margin | 21% | 22% | 23% | 23-25% | 24-26% |
| Adj. EPS | $3.16 | $3.28 | $3.69 | $3.30-3.80 | $3.70-4.30 |
| FCF | $300M | $400M | $470M | $400-600M | $500-700M |
| Capital Return | FY2024 | FY2025E | FY2026E |
|---|---|---|---|
| Dividend per Share | $0 | $0 | $0 |
| Buybacks | $200M | $200-400M | $300-500M |
| Total Capital Return | $200M | $200-400M | $300-500M |
| Credit Rating | Baa2/BBB | Baa2/BBB | Baa2/BBB |
Market Evaluation
COO currently trades at ~22-28x earnings reflecting: (i) selected category-leading contact lens franchise (~25% global share); (ii) selected myopia management secular growth catalyst; (iii) selected fertility/women's health diversification; offset by (iv) selected post-2021 Generate Life Sciences integration; (v) selected vs Johnson & Johnson Acuvue competitive intensity; (vi) selected no dividend.
Selected peer comparison: Johnson & Johnson (JNJ ~15-18x P/E diversified pharma + medtech), Alcon (ALC ~25-28x P/E vision care + surgical), Bausch & Lomb (BLCO ~15-18x P/E vision care), Hologic (HOLX ~15-18x P/E women's health). COO valuation reflects mid-tier vision care positioning with selected myopia management growth optionality.
FY2026 catalysts: (i) myopia management +50%+; (ii) CooperVision daily disposable conversion; (iii) CooperSurgical fertility stability; (iv) capital return acceleration. Risks: (i) Johnson & Johnson competitive intensity; (ii) MiSight competitive substitution; (iii) Generate Life Sciences integration; (iv) currency translation.
Myopia Management and Contact Lens Premium
The FY2026 thesis hinges on Cooper's ability to scale myopia management toward $300-400M + sustain CooperVision daily disposable conversion + maintain CooperSurgical stability. Myopia management trajectory toward $300-400M FY2026 (+50%+) signals selected continued pediatric adoption + international expansion + Brilliant Futures program acceleration.
CooperVision $3.1-3.2B FY2026 (+6-10%) supports total revenue $4.4-4.6B (+5-8%) + adj. EPS $3.70-4.30 (+10-15%). Capital return at $300-500M FY2026 reflecting selected continued buyback prioritization over dividend.
Material risks: (i) myopia management below 25% growth; (ii) MiSight competitive substitution; (iii) Generate Life Sciences integration impairment; (iv) currency translation severe.
FY2026-2027 base case: revenue $4.4-4.6B (+5-8%) + $4.7-5.0B (+5-8%); adj. EPS $3.70-4.30 + $4.10-4.80 (+10-15% growth); myopia management $300-400M + $400-550M; capital return $300-500M + $400-600M. Selected category-leading contact lens franchise + selected myopia management secular optionality + selected disciplined capital allocation support continued compounding through FY2027.